A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Kai Chua Department of Vaccine Clinical Evaluation, Jiangsu Center for Disease Control and Prevention, Nanjing, JS, P. R. ChinaView further author information

Yuemei Hua Department of Vaccine Clinical Evaluation, Jiangsu Center for Disease Control and Prevention, Nanjing, JS, P. R. ChinaView further author information

Hongxing Pana Department of Vaccine Clinical Evaluation, Jiangsu Center for Disease Control and Prevention, Nanjing, JS, P. R. ChinaView further author information

Jingliang Wub Department of Infectious Disease, Huaiyin Center for Disease Control and Prevention, Huai’an, JS, P. R. ChinaView further author information

Dandan Zhub Department of Infectious Disease, Huaiyin Center for Disease Control and Prevention, Huai’an, JS, P. R. ChinaView further author information

Mariano M. Young Jrc Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USAView further author information

Li Luod Clinical Development, Pfizer Vaccine Research, Beijing, P. R. ChinaCorrespondence[email protected]

https://orcid.org/0000-0002-6874-2161 View further author information

Zhuobiao Yic Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USAView further author information

Peter C. Giardinae Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USAView further author information

William C. Gruberc Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USAView further author information

Daniel A. Scottc Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USAView further author information

Wendy Watsonc Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USAView further author information

show all

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date